4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 91 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,160,414 | -31.9% | 1,033,811 | -3.4% | 1.46% | -13.8% |
| Q2 2023 | $19,334,900 | +5.1% | 1,070,000 | 0.0% | 1.69% | +11.6% |
| Q1 2023 | $18,393,300 | +31.5% | 1,070,000 | +69.8% | 1.52% | +39.8% |
| Q4 2022 | $13,992,300 | +260.9% | 630,000 | +13.4% | 1.08% | +230.5% |
| Q2 2022 | $3,877,000 | -53.8% | 555,455 | 0.0% | 0.33% | -13.0% |
| Q1 2022 | $8,398,000 | -31.1% | 555,455 | 0.0% | 0.38% | +9.9% |
| Q4 2021 | $12,187,000 | -59.5% | 555,455 | -50.2% | 0.34% | -54.2% |
| Q3 2021 | $30,084,000 | +12.0% | 1,115,455 | -0.0% | 0.75% | +9.8% |
| Q2 2021 | $26,863,000 | -37.8% | 1,115,555 | +12.1% | 0.68% | -47.0% |
| Q1 2021 | $43,178,000 | +33.5% | 995,354 | +27.5% | 1.29% | +34.1% |
| Q4 2020 | $32,354,000 | – | 780,555 | – | 0.96% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 831,267 | $22,419,000 | 5.52% |
| Aquilo Capital Management, LLC | 1,099,944 | $29,665,000 | 5.39% |
| BVF INC/IL | 2,005,862 | $54,098,000 | 2.11% |
| Casdin Capital, LLC | 1,115,455 | $30,084,000 | 0.75% |
| Soleus Capital Management, L.P. | 120,900 | $3,261,000 | 0.51% |
| Eagle Health Investments LP | 57,090 | $1,540,000 | 0.49% |
| Centiva Capital, LP | 358,863 | $7,220,000 | 0.45% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $106,206,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,003,447 | $27,063,000 | 0.21% |
| Perceptive Advisors | 375,256 | $10,121,000 | 0.15% |